Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia

Case Report: Targeting 2 Antigens as a Promising Strategy in Mixed Phenotype Acute Leukemia: Combination of Blinatumomab With Gemtuzumab Ozogamicin in an Infant With a KMT2A-Rearranged Leukemia

Mixed phenotype acute leukemia (MPAL) accounts for 2-5% of leukemia in children. MPAL are at higher risk of induction failure. Lineage switch (B to M or vice versa) or persistence of only the lymphoid or myeloid clone is frequently observed in biphenotypic/bilineal cases, highlighting their lineage...

Full description

Bibliographic Details
Main Authors: Benoît Brethon, Elodie Lainey, Aurélie Caye-Eude, Audrey Grain, Odile Fenneteau, Karima Yakouben, Julie Roupret-Serzec, Lou Le Mouel, Hélène Cavé, André Baruchel
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
mixed phenotype acute leukemia
infant
children
blinatumomab
gemtuzumab ozogamicin
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.637951/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.637951/full

Similar Items